Myoki, a novel therapeutic peptide, combats muscle atrophy through multiple mechanisms including protein synthesis promotion, degradation inhibition, and satellite cell activation.
Triple anti-atrophy actionMyoki fights muscle wasting through three simultaneous mechanisms — building muscle, preventing breakdown, and activating repair cells
What the researchers found
Myoki peptide: multi-mechanism anti-atrophy action including protein synthesis promotion, degradation inhibition, and satellite cell activation for muscle preservation.
Why it matters
Muscle wasting from aging, cancer, and GLP-1 drugs affects millions. A peptide addressing it through multiple pathways could transform outcomes.
How the study worked
Review of Myoki peptide mechanisms of action in muscle atrophy, covering protein synthesis, degradation, and satellite cell pathways.
What this study cannot tell us
Review of emerging peptide. Clinical data limited. Manufacturing and delivery not detailed.
How to read the evidence
Review of emerging therapeutic peptide with mechanistic characterization.
When this study was published
Published in 2025.
The bigger picture
As GLP-1 drugs cause muscle loss in millions of users, a multi-mechanism anti-atrophy peptide like Myoki could become an essential companion therapy.
Questions still open
- Could Myoki prevent muscle loss during GLP-1 drug therapy?
- Is Myoki more effective than exercise for muscle preservation?
- What is Myoki's mechanism of satellite cell activation?
Common questions
What is Myoki?
Could it help with muscle loss from GLP-1 drugs?
Read the original research
The therapeutic potential of Myoki, a novel peptide in muscle atrophy: mechanisms and applications.
Frontiers in pharmacology, 17, 1663850
Citation
Kim, Eun Mi; Kim, Seon Soo; Hyun, Yong Geon; Lee, Su Yeon; Chung, Yong Ji. (2026). The therapeutic potential of Myoki, a novel peptide in muscle atrophy: mechanisms and applications.. Frontiers in pharmacology, 17, 1663850. https://doi.org/10.3389/fphar.2026.1663850